Abstract
Objectives: Cystic fibrosis (CF) patients suffer from severe chronic lung infections that are caused mainly by Pseudomonas aeruginosa. As this highly adaptable pathogen is increasingly resistant to antibiotics, the development of new antimicrobial treatments is of major interest. Antimicrobial photodynamic therapy (aPDT) combines the use of photosensitizers (PS) and light to locally generate reactive oxygen species, including singlet oxygen (1O2), at the infection site. In this work, ruthenium (II) PS complexes were incorporated into polymeric micelles and vesicles to overcome the limited solubility and stability of the neat complexes, and to facilitate their delivery through the highly viscous airway mucus. Further, on-demand bacterial enzyme-triggered release of PS should minimize lung tissue damage, while maximizing local bacterial killing efficiency.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
More From: Journal of Cystic Fibrosis
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
